63 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Cox4i2tm1Hutt/Cox4i2tm1.1Jlob Thtm1(cre)Te/Th+ involves: 129X1/SvJ * C57BL/6	abnormal physiological response to hypoxia	J:302384
Dbhtm2(Th)Rpa/Dbh+ Thtm1Rpa/Thtm1Rpa involves: 129S7/SvEvBrd	abnormal nervous system physiology	J:30404
	adipsia	J:30404
	aphagia	J:30404
	decreased body size	J:30404
	decreased body weight	J:30404
	decreased brain size	J:30404
	decreased dopamine level	J:30404
	decreased locomotor activity	J:30404
	decreased stereotypic behavior	J:30404
	hunched posture	J:30404
	poor grooming	J:30404
	premature death	J:30404
	weight loss	J:30404
Dbhtm2(Th)Rpa/Dbh+ Thtm1Rpa/Thtm1Rpa involves: 129S7/SvEvBrd * C57BL/6J	abnormal gait	J:58125
	akinesia	J:58125
	catalepsy	J:58125
	decreased compensatory feeding amount	J:58125
	decreased food intake	J:58125
	decreased locomotor activity	J:58125
	hunched posture	J:58125
	hyperactivity	J:58125
	hyporesponsive to tactile stimuli	J:58125
	impaired behavioral response to addictive substance	J:58125
	impaired coordination	J:58125
	increased stereotypic behavior	J:58125
	premature death	J:58125
Dbhtm2(Th)Rpa/Dbh+ Thtm5Rpa/Thtm5Rpa involves: 129S4/SvJaeSor	abnormal avoidance learning behavior	J:154773
	decreased dopamine level	J:154773
Dbhtm2(Th)Rpa/Dbh+ Thtm5Rpa/Thtm5Rpa involves: 129S4/SvJaeSor * C57BL/6	abnormal eating behavior	J:110806
	abnormal motor capabilities/coordination/movement	J:110806
	abnormal postnatal growth	J:110806
	decreased body weight	J:110806
	decreased compensatory feeding amount	J:110806
	decreased dopamine level	J:110806
	hyperactivity	J:110806
	impaired coordination	J:110806
	increased food intake	J:110806
	increased thigmotaxis	J:110806
	normal mortality/aging	J:110806
Dbhtm2(Th)Rpa/Dbh+ Thtm5Rpa/Thtm5Rpa involves: 129S4/SvJaeSor * C57BL/6	aphagia	J:110806
	bradykinesia	J:110806
	decreased body weight	J:110806
	decreased dopamine level	J:110806
	decreased locomotor activity	J:110806
	premature death	J:110806
	weight loss	J:110806
Grprtm1Jfb/Grprtm1Jfb Slc17a6tm1Kldr/Slc17a6tm1Kldr Thtm1(cre)Te/Th+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6	excessive scratching	J:167752
Med22tm1a(EUCOMM)Hmgu/Med22+ Thtm1(cre)Te/Th+ involves: 129X1/SvJ * C57BL/6N	normal renal/urinary system phenotype	J:300239
Med22tm1a(EUCOMM)Hmgu/Med22tm1a(EUCOMM)Hmgu Thtm1(cre)Te/Th+ involves: 129X1/SvJ * C57BL/6N	preweaning lethality, complete penetrance	J:300239
Ndufa4l2tm1.1Jlob/Ndufa4l2tm1.2Jlob Thtm1(cre)Te/Th+ involves: 129S/Sv * 129X1/SvJ * C57BL/6NCrl * C57BL/6NTac	abnormal physiological response to hypoxia	J:302384
Psmc1tm1Maye/Psmc1tm1.1Maye Thtm1(cre)Te/Th+ involves: 129X1/SvJ * CD-1	abnormal noradrenaline level	J:138991
	alpha-synuclein inclusion body	J:138991
	decreased body size	J:138991
	decreased dopamine level	J:138991
	gliosis	J:138991
	neuron degeneration	J:138991
	postnatal lethality	J:138991
Psmc1tm1Maye/Psmc1tm1Maye Thtm1(cre)Te/Th+ involves: 129X1/SvJ * CD-1	abnormal noradrenaline level	J:138991
	alpha-synuclein inclusion body	J:138991
	decreased body size	J:138991
	decreased dopamine level	J:138991
	gliosis	J:138991
	neuron degeneration	J:138991
	postnatal lethality, complete penetrance	J:138991
Sdhdtm1Jlob/Sdhdtm2Jlob Thtm1(cre)Te/Th+ involves: 129S1/Sv * 129X1/SvJ	abnormal adrenal chromaffin cell morphology	J:186713
	abnormal dopaminergic neuron morphology	J:186713
	bradykinesia	J:186713
	decreased birth body size	J:186713
	decreased dopamine level	J:186713
	decreased locomotor activity	J:186713
	decreased neuron number	J:186713
	loss of dopaminergic neurons	J:186713
	normal neoplasm	J:186713
	oxidative stress	J:186713
	premature death	J:186713
Slc17a6tm1Kldr/Slc17a6tm1Kldr Thtm1(cre)Te/Th+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal pain threshold	J:167752
	decreased chemically-elicited antinociception	J:167752
	excessive scratching	J:167752
	normal homeostasis/metabolism phenotype	J:167752
	increased pruritus	J:167752
	increased thermal nociceptive threshold	J:167752
	mixed cellular infiltration to dermis	J:167752
	skin lesions	J:167752
	thick epidermis	J:167752
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0 Thtm1(cre)Te/Th+ involves: 129X1/SvJ * C57BL/6 * FVB/N	adrenal gland hyperplasia	J:186696
	increased metastatic potential	J:186696
	increased neuroblastoma incidence	J:186696
Thtm1Srt/Thtm1Srt Tyrc/Tyrc involves: 129S2/SvPas * C57BL/6J * ICR	abnormal adrenaline level	J:54692
	abnormal noradrenaline level	J:54692
	decreased dopamine level	J:54692
	prenatal lethality, complete penetrance	J:54692
Thtm2Te/Thtm2Te involves: 129X1/SvJ * C57BL/6	bradykinesia	J:93552
	decreased body size	J:93552
	decreased dopamine level	J:93552
	decreased noradrenaline level	J:93552
	increased serotonin level	J:93552